Milestones over the development of SB3, a trastuzumab biosimilar.

Pivot, Xavier; Bondarenko, Igor; Petit, Thiery; Curtit, Elsa

Pivot, Xavier; Bondarenko, Igor; Petit, Thiery; Curtit, Elsa.

Affiliation

Pivot X; Centre Paul Strauss, Porte de l'Hopital Strasbourg, France.
Bondarenko I; Oncology & Medical Radiology Department, Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine.
Petit T; Centre Paul Strauss, Porte de l'Hopital Strasbourg, France.
Curtit E; Department of Medical Oncology, University Hospital Of Besançon, France.

Future Oncol ; 14(27): 2795-2803, 2018 Nov.

Article in En | MEDLINE | ID: mdl-29927335

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Biosimilar Pharmaceuticals/therapeutic use; Breast Neoplasms/therapy; Drug Development; Trastuzumab/therapeutic use; Animals; Antineoplastic Combined Chemotherapy Protocols/economics; Antineoplastic Combined Chemotherapy Protocols/pharmacology; Biosimilar Pharmaceuticals/economics; Biosimilar Pharmaceuticals/pharmacology; Breast Neoplasms/economics; Breast Neoplasms/pathology; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Drug Costs; Female; Humans; Mastectomy; Neoadjuvant Therapy/economics; Neoadjuvant Therapy/methods; Receptor, ErbB-2/antagonists & inhibitors; Receptor, ErbB-2/metabolism; Trastuzumab/economics; Trastuzumab/pharmacology; Treatment Outcome; Xenograft Model Antitumor Assays

Key words

biosimilar; breast cancer; trastuzumab

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Biosimilar Pharmaceuticals / Trastuzumab / Drug Development Type of study: Clinical_trials / Prognostic_studies Language: En Journal: Future Oncol Year: 2018 Type: Article Affiliation country: France

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google